Sezary Syndrome Clinical Trials

6 recruiting

Sezary Syndrome Trials at a Glance

9 actively recruiting trials for sezary syndrome are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Atlanta, Stanford, and Baltimore. Lead sponsors running sezary syndrome studies include City of Hope Medical Center, Kyowa Kirin Co., Ltd., and Fondazione Italiana Linfomi - ETS.

Browse sezary syndrome trials by phase

Treatments under study

About Sezary Syndrome Clinical Trials

Looking for clinical trials for Sezary Syndrome? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Sezary Syndrome trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Sezary Syndrome clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 2

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Mycosis FungoidesLymphomatoid PapulosisSezary Syndrome
Memorial Sloan Kettering Cancer Center58 enrolled8 locationsNCT03587844
Recruiting
Phase 2

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

Cutaneous T Cell LymphomaFungoides Mycosis Sezary Syndrome
University of Michigan Rogel Cancer Center23 enrolled1 locationNCT05956041
Recruiting

Extracorporeal Photopheresis in Sezary Syndrome

Sezary Syndrome
Oleg E. Akilov, MD, PhD20 enrolled3 locationsNCT05157581
Recruiting

Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma

Cutaneous T Cell LymphomaCutaneous T-Cell Lymphoma/Mycosis FungoidesCutaneous T-Cell Lymphoma/Sezary Syndrome
Fondazione Italiana Linfomi - ETS400 enrolled18 locationsNCT06588868
Recruiting
Phase 2

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

Primary Cutaneous T-Cell Non-Hodgkin LymphomaStage IB Mycosis Fungoides and Sezary Syndrome AJCC v8Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8+5 more
City of Hope Medical Center34 enrolled3 locationsNCT04930653
Recruiting

Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance

Mycosis FungoidesSezary Syndrome
Kyowa Kirin Co., Ltd.15 enrolled6 locationsNCT07132567
Recruiting

A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab

Recurrent Mycosis FungoidesRecurrent Sezary SyndromeRefractory Mycosis Fungoides+6 more
City of Hope Medical Center100 enrolled10 locationsNCT07003100
Recruiting
Phase 2

Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome

Mycosis FungoidesSezary Syndrome
Stanford University30 enrolled1 locationNCT04256018
Recruiting

Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome.

Mycosis FungoidesSezary Syndrome
Lund University Hospital120 enrolled1 locationNCT04904146